HPT/Axis is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules that selectively target hormone pathways related to the treatment of serious men’s health conditions. Our drug discovery and development programs focus is on small molecules that selectively modulate the effects of progestins, estrogens, and androgens, essential classes of hormones in HPTA regulation and control. These drugs are important in medical conditions that include cancer, osteoporosis, muscle wasting, obesity, chronic obstructive pulmonary disease, chronic kidney disease (hemodialysis), sarcopenia, frailty, male contraception, and others. HPT/Axis is committed to effective execution in all of these areas to ensure a healthy future for our business, solidify technology leadership, and create shareholder value.
To
learn more, we invite you return often for updates, news, and to explore our
site.
E-mail Alerts
You may automatically receive HPT/Axis, Inc. information by e-mail. For e-mail notification, please enter your e-mail address below and click Subscribe.
Contact Us • Terms of Use• Privacy Policy • Legal Notices
HPT/Axis, Inc. © 2008